Changes in Dietary Supplement Use During the COVID-19 Pandemic

项目摘要 膳食补充剂被超过一半的美国人口消费，购买量有所增加 自2019冠状病毒病大流行爆发以来，尽管补充剂的广泛使用， 美国联邦法律禁止FDA对补充剂的安全性或有效性进行预筛选 而是依靠工业来履行这些职责。FDA在很大程度上只能采取执法行动 只有在产品与虚假声明或伤害有关时才能上市。最近补充剂销售的上升 对消费者安全的担忧，特别是那些可能加剧了与流行病有关的担忧的消费者， 他们的健康和安全出于各种原因。在大流行的头几个月里， 心理困扰被记录在案，在美国，抑郁症状估计增加了三倍 成年人在这段时间与流行病相关的心理压力加剧可能反过来 增加消费者使用声称可以增强免疫力、增加体重 损失，或促进健康的其他方式与错误的信念，这些产品将保护他们免受感染 或防止体重增加。据我们所知，没有研究调查过潜在危险的 在大流行期间，也没有检查过补充剂在弱势群体中使用的危险性是否过高。这 U01 HL 145386的行政补充：“整合生命过程方法，生物和数字 支持心肺疾病流行病学研究的表型”，将使我们能够估计 2019冠状病毒病大流行期间膳食补充剂的使用流行率和使用流行率的变化，以及 评估这些使用模式是否与大流行的过程有关， 以及这些问题与联合国儿童基金会在 流行病这项行政补助金加强和扩大了父母补助金的目标， 我们会扩大收集没有明确风险评估的普遍风险数据的范围（a 目标1的组成部分），并通过全面的空间和时间分析， 这种行为风险因素的特征，以及它与其他心脏和肺风险因素的相互作用， 疾病

Project Abstract Dietary supplements are consumed by more than half of the US population, and purchasing has increased precipitously since the onset of the COVID-19 pandemic. Despite the widespread use of supplements by consumers of all ages, US federal law prohibits the FDA from prescreening supplements for safety or efficacy and instead relies on industry to perform these duties. FDA is largely constrained to taking enforcement action only postmarket once a product is linked with false claims or injury. The recent uptick in supplement sales raises concerns for the safety of consumers, especially those who may have heightened pandemic-related fears about their health and safety for a variety of reasons. Within the first few months of the pandemic, widespread psychological distress was documented, with an estimated threefold increase in depressive symptoms in US adults during this time. It is plausible that heightened pandemic-related psychological distress may in turn increase the likelihood that consumers will use supplements sold with claims to boost immunity, increase weight loss, or promote health in other ways with the mistaken belief that these products will protect them from infection or prevent weight gain. No studies to our knowledge have investigated changes in use of potentially dangerous supplements during the pandemic nor examined plausibly elevated risk of use in vulnerable groups. This administrative supplement to U01 HL145386: “Integrating Lifecourse Approaches, Biologic and Digital Phenotypes in Support of Heart and Lung Disease Epidemiologic Research,” will allow us to estimate the prevalence of use and change of prevalence of use of dietary supplements during the COVID-19 pandemic and to evaluate whether these patterns of use relate to the course of the pandemic, whether they are more frequent in vulnerable populations as well as their relation with changes in mental health status during the course of the pandemic. This administrative supplement strengthens and expands the goals of the parent grant by allowing us to expand the scope of data collection of prevalent exposures without a well-characterized risk profile (a component of Aim 1) and understand its impact on the pandemic through thorough spatial and temporal characterization of this behavioral risk factor, as well as its interaction with other risk factors for heart and lung diseases.